AOD-9604

Human growth hormone fragment 176–191 studied for fat metabolism and body-composition support, with a safety-focused clinical program.

Evidence: Human Data + Preclinical Function: Metabolic / Body Composition Class: hGH C‑terminal fragment

Explore calculators for this peptide

Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for AOD-9604. All values are placeholders and must be aligned with your own research protocol.

Open AOD-9604 in calculators →

Research focus & potential applications

AOD‑9604 is a modified fragment of human growth hormone (amino acids 176–191) designed to retain fat‑metabolism activity without the growth‑promoting and IGF‑1–elevating effects of full‑length hGH. Preclinical work and human trials investigate its capacity to enhance lipolysis, reduce lipogenesis and support fat oxidation, while maintaining a glucose‑neutral and IGF‑1‑neutral safety profile.

Evidence score (research confidence)

Human safety, mixed efficacy

Score reflects a substantial clinical safety program (multiple randomized trials, hundreds of participants) with consistent metabolic safety signals, contrasted with more modest and mixed efficacy outcomes for weight loss. It is a research confidence indicator, not a guarantee of clinical benefit.

Targets lipolytic pathways in adipose tissue Stimulates lipolysis & fat oxidation, inhibits lipogenesis (preclinical) Human trials: safety & glucose neutrality, modest weight‑loss signals No IGF‑1 elevation or GH‑like growth effects

Research areas & putative benefits

How AOD‑9604 is being explored in preclinical and human research – framed as metabolic signals, not treatment promises.

Enhancement of lipolysis and fat oxidation in adipose tissue, with reduced weight gain in obese animal models despite similar caloric intake.
Suppression of lipogenesis and potential support for a more favorable body‑composition trajectory (less fat accumulation) under caloric surplus conditions.
Maintenance of normal glucose tolerance, insulin sensitivity and IGF‑1 levels in clinical trials, in contrast to full hGH.
Exploratory use in joint and cartilage repair models, where hGH fragments have been evaluated for tissue healing, although human evidence remains limited.

Mechanism stack

Key pathways implicated when AOD‑9604 is used in adipose and metabolic research.

Fragment design

hGH 176–191 domain

AOD‑9604 corresponds to the C‑terminal fragment (176–191) of human growth hormone, engineered to isolate the fat‑modulating region while avoiding activation of classical GH growth and IGF‑1 signaling.

Adipose signaling

cAMP‑driven lipolysis

Preclinical data indicate that AOD‑9604 up‑regulates lipolytic activity in adipose tissue and activates cAMP‑dependent cascades, ultimately stimulating hormone‑sensitive lipase to mobilize stored triglycerides.

Fat turnover

Lipolysis ↑, lipogenesis ↓

Studies suggest a dual effect: increased breakdown of stored fat (lipolysis) and reduced synthesis of new fat (lipogenesis), promoting greater fat oxidation and less adipose accumulation over time.

Metabolic safety

No GH receptor / IGF‑1 drive

Unlike full‑length hGH, AOD‑9604 does not significantly bind GH receptors or elevate IGF‑1 in clinical studies, and has shown neutral effects on glucose tolerance and insulin sensitivity in obese subjects.

Evidence snapshot

Selected findings from animal, mechanistic and human studies on AOD‑9604.

Model / context	Observation	Notes
Obese animal models (diet‑induced) Preclinical adipose	AOD‑9604 reduced weight gain versus control over several weeks, with increased adipose lipolytic activity and unchanged food intake.	Consistent with a direct effect on fat metabolism rather than appetite suppression.
Human obesity trials (short–medium term) Randomized clinical trials	Multiple double‑blind, placebo‑controlled studies indicated that AOD‑9604 was well tolerated with no serious drug‑related adverse events, neutral effects on glucose and insulin, and no IGF‑1 elevation.	Safety profile broadly comparable to placebo in obese populations, including up to about 24 weeks of exposure.
Human weight‑loss efficacy Clinical efficacy signal	Some trials reported small additional weight loss versus placebo, but larger and longer studies did not show robust, statistically significant superiority when combined with diet and exercise.	Development for obesity was discontinued primarily due to insufficient efficacy, not due to safety concerns.
Mechanistic in vitro / ex vivo Mechanistic	Fragment 176–191 and AOD‑9604 increased lipid oxidation and hormone‑sensitive lipase activity in adipose systems without triggering classical GH growth pathways.	Reinforces a distinction between metabolic and growth‑hormone‑like effects.

Risk frame & unknowns

How to interpret AOD‑9604 data in light of its development history.

Important research caveats

Clinical development for obesity was halted because weight‑loss efficacy did not meet regulatory thresholds, even though safety outcomes were favorable.
Long‑term outcome data (for example cardiometabolic events and mortality) are not available; existing trials are limited in duration and scope.
Most mechanistic support for fat‑loss effects originates from animal and ex vivo studies; translation to diverse human populations is uncertain.
Use outside regulated research or supervised clinical environments raises questions about dosing, quality control and combination with other agents.

This dossier summarizes mechanistic, preclinical and clinical findings on AOD‑9604 for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.